Blastic plasmacytoid dendritic cell neoplasm: challenges and future prospects [0.03%]
颗粒细胞浆样树突状细胞肿瘤的挑战和未来前景
Amy M Trottier,Sonia Cerquozzi,Carolyn J Owen
Amy M Trottier
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare CD4+ CD56+ myeloid malignancy that is challenging to diagnose and treat. BPDCN typically presents with nonspecific cutaneous lesions with or without extra-cutaneous manifestatio...
Impact of obinutuzumab alone and in combination for follicular lymphoma [0.03%]
奥英利珠单抗单药及联合治疗滤泡性淋巴瘤的影响
Maryam Sarraf Yazdy,Bruce D Cheson
Maryam Sarraf Yazdy
Although rituximab-based chemoimmunotherapy prolongs the survival of patients with follicular lymphoma (FL), this disease is considered incurable in most patients. Thus, new therapies are needed not only for those in the relapsed/refractory...
Complications and management of coagulation disorders in leukemia patients [0.03%]
急性白血病凝血功能障碍的并发症及处理
Deepesh Lad,Arihant Jain,Subhash Varma
Deepesh Lad
Patients with leukemia are predisposed to various coagulation abnormalities. Thrombosis and bleeding continue to be a major cause of morbidity and mortality in leukemias. The pathophysiology of these disorders is unique, and not only the di...
Use of carfilzomib in second-line therapy and beyond for relapsed multiple myeloma [0.03%]
卡非佐米在复发性多发性骨髓瘤二线及二线以后治疗中的应用
Divaya Bhutani,Jeffrey A Zonder
Divaya Bhutani
The development of proteasome inhibitors has been a major advance in therapy of multiple myeloma, accounting, in part, for the significant increase in the survival of patients diagnosed with this disease. Bortezomib was the first proteasome...
Clinical potential of midostaurin in advanced systemic mastocytosis [0.03%]
Midostaurin在晚期系统性肥大细胞增多症的临床潜力
Marie Olivia Chandesris,Gandhi Damaj,Olivier Lortholary et al.
Marie Olivia Chandesris et al.
Advanced (Ad) systemic mastocytoses (SM) include aggressive SM (ASM) and mast cell leukemia (MCL) with or without an associated clonal hematological non-mast cell lineage disease (AHNMD). They are rare (80%). We herein present a review of t...
Heather R Ferguson Bennit,Amber Gonda,Laura J Oppegard et al.
Heather R Ferguson Bennit et al.
Exosomes are nanosized lipid vesicles secreted into blood and other body fluids and serve as vehicles for intercellular communication. Despite being an important component of the tumor microenvironment (TME), exosomal targeting and uptake i...
Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma [0.03%]
程序性死亡配体-1阻断在霍奇金淋巴瘤治疗中的应用
Melody B Oncale,Hossein Maymani,Loretta J Nastoupil
Melody B Oncale
Immunotherapy is a rapidly evolving therapeutic option in the treatment of lymphoma. Neoplastic cells evade immune recognition through the programmed death (PD)-1/PD-ligand immune checkpoint pathway. Several novel agents have been developed...
Waldenström macroglobulinemia: biology, genetics, and therapy [0.03%]
Waldenstrom巨球蛋白血症：生物学、遗传学和治疗手段
Jonas Paludo,Stephen M Ansell
Jonas Paludo
Waldenström macroglobulinemia (WM) is a distinct clinicopathologic entity characterized by the presence of a lymphoplasmacytic lymphoma, a non-Hodgkin lymphoma, and IgM monoclonal gammopathy. WM is an indolent, uncommon malignancy mostly a...
Managing treatment-related peripheral neuropathy in patients with multiple myeloma [0.03%]
防治多发性骨髓瘤患者的治疗相关性外周神经病变
Sara Grammatico,Laura Cesini,Maria Teresa Petrucci
Sara Grammatico
Peripheral neuropathy is one of the most important complications of multiple myeloma treatment. Neurological damage can be observed at the onset of the disease, due to the effect of monoclonal protein or radicular compression, but more ofte...
Assessment and monitoring of patients receiving chemotherapy for multiple myeloma: strategies to improve outcomes [0.03%]
评估和监测多发性骨髓瘤化疗患者：改善预后的策略
Beth Faiman,Jason Valent
Beth Faiman
Improved understanding as to the biology of multiple myeloma (MM) and the bone marrow microenvironment has led to the development of new drugs to treat MM. This explosion of new and highly effective drugs has led to dramatic advances in the...